Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 6.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 135,554 shares of the company’s stock after purchasing an additional 7,685 shares during the quarter. California State Teachers Retirement System owned 0.06% of Allogene Therapeutics worth $289,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ALLO. Lynx1 Capital Management LP raised its holdings in shares of Allogene Therapeutics by 75.3% during the 4th quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock worth $23,163,000 after acquiring an additional 4,672,349 shares during the period. Foresite Capital Management VI LLC purchased a new position in shares of Allogene Therapeutics in the 4th quarter valued at about $7,345,000. Patient Square Capital LP purchased a new position in Allogene Therapeutics during the 4th quarter worth approximately $3,174,000. Gilead Sciences Inc. purchased a new position in Allogene Therapeutics during the 4th quarter worth approximately $2,464,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Allogene Therapeutics by 30.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock valued at $7,586,000 after purchasing an additional 831,146 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Trading Down 3.4%

Shares of NASDAQ:ALLO opened at $1.40 on Friday. Allogene Therapeutics, Inc. has a 1 year low of $0.86 and a 1 year high of $3.78. The business has a fifty day simple moving average of $1.34 and a 200 day simple moving average of $1.74. The firm has a market cap of $306.22 million, a price-to-earnings ratio of -0.90 and a beta of 0.31.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). On average, sell-side analysts forecast that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Wall Street Analyst Weigh In

ALLO has been the subject of several research reports. Piper Sandler reduced their price objective on Allogene Therapeutics from $9.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Wednesday, May 14th. HC Wainwright decreased their target price on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 19th. Oppenheimer cut their price target on Allogene Therapeutics from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 14th. Finally, Citizens Jmp cut Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).